BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

UltraGreen.ai expands Asia presence following propriety Imaging system approval in South and SEA markets

March 12, 2026 | News

IC-FlowTM Imaging System V2 has received regulatory approval across India, Thailand, Philippines, and Bangladesh markets, bringing the system's global regulatory footprint to 45 territories.



UltraGreen.ai Limited, a global leader in fluorescence-guided surgery and digital health solutions, today announced that its IC-FlowTM Imaging System V2 has received regulatory approval across multiple South and Southeast Asian markets, bringing the system's global regulatory footprint to 45 territories. This development supports the Company's strategy to broaden access to its fluorescence imaging technologies in the Asia Pacific (APAC) region.

The approvals include registration with the Central Drugs Standard Control Organisation (CDSCO), Government of India for India, approval by the Thai Medical Device Control Division for Thailand, approval by the Centre for Device Regulation, Health and Research (CDRRHR) for the Philippines, and approval by the Directorate General of Drug Administration (DGDA) for Bangladesh. These regulatory clearances authorise UltraGreen to commercialise the IC-FlowTM Imaging System V2 in the respective countries in accordance with local regulatory requirements.

The IC-FlowTM Imaging System V2 is a hand-held near-infrared (NIR) fluorescence imaging platform developed to support intraoperative visualisation during open surgical procedures. Across the newly approved territories, the system is used to assess tissue perfusion and flap circulation for plastic and microÃ¢â?¬â??reconstructive surgery, support organ transplant procedures, and visualise lymphatic flow.

"This series of regulatory approvals reflects our ongoing commitment to expanding access to compliant fluorescence imaging technologies across the region," said **Declan Cassells, Chief Operating Officer of UltraGreen**. "Each approval enables us to actively engage with healthcare institutions, distributors, and clinical partners while ensuring adherence to local regulatory frameworks."

Quek Mei Ling, Chief Business Officer (APAC) of UltraGreen, commented, "South and Southeast Asia represent important and growing healthcare markets. These milestones strengthen our ability to build long-term partnerships, support

clinical education initiatives, and advance responsible commercialisation in alignment with quality and compliance standards."

The clearances build on the Company's recent approvals for Verdye (Indocyanine Green, pharmaceutical product) in the Philippines and the IC-FlowTM Imaging System V2 in Malaysia. With these latest milestones, UltraGreen continues to reinforce its regulatory presence across multiple jurisdictions. The IC-FlowTM Imaging System V2 is also approved in Singapore and New Zealand within the APAC region, as well as in the United States and Europe, reflecting the Company's broader global expansion strategy.